Moderna Vaccine REJECTED! Is Big Pharma Failing Us?

Well, folks, it seems like Moderna has hit a snag in its quest to bring its mRNA influenza vaccine, mRNA-1010, to the American market. The FDA has refused to even *begin* reviewing the application, and the reason why is causing quite a stir.

Moderna Vaccine REJECTED! Is Big Pharma Failing Us...

According to the FDA, Moderna's application hinges solely on a comparison between its mRNA-1010 and an existing, already-approved standard-dose seasonal flu vaccine. The agency claims that this doesn't constitute an "adequate and well-controlled" study. They argue that the comparator – the vaccine it's being compared to – doesn't reflect the "best-available standard of care." Moderna, naturally, disagrees, saying that this directly contradicts prior communications with the FDA.

Moderna's CEO, Stéphane Bancel, didn't mince words. He stated it "should not be controversial" to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator. Furthermore, he claims the study design was discussed and *agreed upon* with the FDA's Center for Biologics Evaluation and Research (CBER) *before* the study even began. Now that's a sticky situation.

Now, Moderna isn't just claiming to be different; they say their vaccine is *better*. Last year, the company reported that mRNA-1010 demonstrated a 26.6% greater effectiveness compared to an approved annual flu shot from GSK. That's a significant margin, and you can see why they're pushing so hard.

The company has requested a meeting with the FDA to get some clarity on what they need to do to move forward. It’s a bit like being told “no,” but not knowing exactly *why* in a way that you can fix. Very frustrating for Moderna, I'm sure.

It's worth noting that this news comes on the heels of revised U.S. childhood immunization guidelines, which have scaled back recommendations for routine vaccination against several infectious diseases, including – you guessed it – influenza. The timing is certainly interesting, to say the least.

While the FDA slams the brakes on mRNA-1010 here in the States, the vaccine is currently under review in the European Union, Canada, and Australia. Moderna is anticipating potential approvals in those regions sometime in late 2026 or 2027. So, while Americans might have to wait, it's possible that the rest of the world will be rolling up their sleeves for mRNA flu shots before we do. Existing FDA-approved influenza vaccines, by the way, are currently manufactured by companies like AstraZeneca and Sanofi.